Abstract 303: Risk Factors for Venous Thromboembolism (VTE) among Patients with Neurologic Disease and Leg Paresis: A Population-based Case-control Study.
Background: Whether VTE risk can be further stratified among patients with neurologic disease and leg paresis is unknown.
Objective: To identify independent risk factors for deep vein thrombosis (DVT) and pulmonary embolism (PE) among patients with neurologic disease and leg paresis.
Methods: Using the population-based resources of the Rochester Epidemiology Project, we identified all Olmsted County, MN residents with incident DVT or PE over the 45-year period, 1966 to 2010. We performed a case-control study nested within the Olmsted County population with incident VTE associated with neurologic disease and leg paresis over the 18-year period, 1988-2010 (n=192). For each VTE case, we identified 1 Olmsted County resident with neurologic disease, leg paresis and no VTE (control) matched to each case on sex, date of birth (+/- 5 years), calendar year (+/- 1 year) and duration of medical records. Using conditional logistic regression, we tested duration of paresis (index-3 months, 3-12 months, and > 12 months), paresis etiology, and degree of immobility as potential risk factors for VTE after adjusting for other known VTE risk factors, including hospitalization for major surgery or acute medical illness, trauma/fracture, and active cancer.
Results: In univariate analyses of the 192 pairs, trauma/fracture, hospitalization for major surgery or for acute medical illness, active cancer, duration of paresis, and degree of immobility were associated with VTE. In the multivariable analysis, hospitalization for acute medical illness, active cancer, degree of immobility (ambulatory without/with assistance, function from a wheelchair base, bed bound; OR: 2.60; 95%Cl: 1.65-4.11); p=<0.0001) were independent predictors of VTE.
Conclusion: Among patients with neurologic disease and leg paresis, VTE risk can be further stratified by hospitalization for acute medical illness, active cancer and degree of immobility; these patients should be considered for VTE prophylaxis.
Author Disclosures: K.P. Cohoon: Research Grant; Significant; Research reported in this publication was supported in part by grants from the National Heart, Lung, and Blood Institute under Award Numbers K12HL83141 (a training grant in Vascular Medicine [K.P.C.]). K.L. Andrews: None. A.A. Ashrani: None. T.M. Petterson: None. K.R. Bailey: None. J.A. Heit: Research Grant; Significant; Research reported in this publication was supported in part by grants from the National Heart, Lung, and Blood Institute under Award Numbers R01HL66216 and K12HL83141.
- © 2015 by American Heart Association, Inc.